Rigel Pharmaceuticals, Inc. (RIGL) Guidance & Earnings Results

On 2026-08-04 Rigel Pharmaceuticals, Inc. raised guidance: "FY2026 total revenues raised to $285-295M from prior range (not stated); net product sales (ex-VEPPANU) $255-265M; contract revenues…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

RIGLRigel Pharmaceuticals, Inc.Follow RIGL — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 899.1M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 2 Nov, in 9 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
4 Aug 26	Raised	FY2026 total revenues raised to $285-295M from prior range (not stated); net product sales (ex-VEPPANU) $255-265M; contract revenues ~$30M · full year
5 May 26	Reaffirmed	FY26 total revenue guidance of $275-$290 million, net product sales of $255-$265 million · full year
3 Mar 26	Lowered	2026 total revenue midpoint $282.5M vs 2025 actual $294.3M
12 Jan 26	Raised	2026 total revenue $275-290M, net product sales $255-265M, positive net income · full year
4 Nov 25	Raised	Total revenue ~$285-290M, net product sales $225-230M · full year
5 Aug 25	Raised	FY2025 total revenue $270-280M (raised from prior); net product sales $210-220M; includes $40M non-cash contract revenue from Lilly · full year

Rigel Pharmaceuticals, Inc. — questions

What guidance did Rigel Pharmaceuticals, Inc. give?: On 2026-08-04: "FY2026 total revenues raised to $285-295M from prior range (not stated); net product sales (ex-VEPPANU) $255-265M; contract revenues ~$30M"
When does Rigel Pharmaceuticals, Inc. report earnings?: Rigel Pharmaceuticals, Inc.'s next earnings report is expected on 2026-11-02.

Every figure on this page comes from Rigel Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.